Effects of cerivastatin on lipid profiles, lipid peroxidation and platelet and endothelial activation in renal transplant recipients.
Caillard
S
S
Nephrology-Transplantation Department, CHU, Strasbourg, France.
Leray
C
C
Kunz
K
K
Gachet
C
C
Offner
M
M
Wiesel
M L
ML
Hannedouchte
T
T
Cazenave
J P
JP
Moulin
B
B
D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000502:physiology*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011725:Pyridines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D008055:Lipids; D011725:Pyridines; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; C086276:cerivastatin